Locust Walk Insights SUBSCRIBE TO OUR INSIGHTS Linkedin Twitter Youtube Instagram CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process Negotiation Partnering Quarterly Reports ARCHIVE 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 LOCUST WALK INSIGHTS 2024 Q3 Report: Global Trends in Biopharma Transactions October 9, 2024 2024 Q2 Report: Global Trends in Biopharma Transactions July 18, 2024 2024 Q1 Report: Global Trends in Biopharma Transactions April 8, 2024 Overview of AI in Biotech April 3, 2024 2023 Year-In-Review Report: Global Trends in Biopharma Transactions January 6, 2024 2023 Q3 Report: Global Trends in Biopharma Transactions October 9, 2023 2023 Q2 Report: Global Trends in Biopharma Transactions July 10, 2023 Deal Makers of Japan, Volume 3 May 31, 2023 2023 Q1 Report: Global Trends in Biopharma Transactions April 10, 2023 RNA Therapeutics Landscape Overview February 22, 2023 RNA Therapeutics Landscape Overview February 22, 2023 2022 Year In Review Report: Global Trends in Biopharma Transactions January 8, 2023 2022 Q3 Report: Global Trends in Biopharma Transactions October 11, 2022 2022 Q2 Report: Global Trends in Biopharma Transactions July 12, 2022 2022 Q1 Report: Global Trends in Biopharma Transactions April 8, 2022 Locust Walk Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies April 5, 2022 Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players March 31, 2022 2021 Year End Report January 10, 2022 Bought Not Sold October 13, 2021 2021 Q3 Report: Global Trends in Biopharma Transactions October 7, 2021 iPSC Market Overview October 4, 2021 2021 Q2 Report: Global Trends in Biopharma Transactions July 12, 2021 Crossover Evolution: The Evolving Role of the Crossover Financing Round April 28, 2021 2021 Q1 Report: Global Trends in Biopharma Transactions April 21, 2021 Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC April 2, 2021 Locust Walk 2020 Year End Report January 28, 2021 Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital December 14, 2020 Q3 Report: Global Trends in Biopharma Transactions October 19, 2020 Panel Recording! Knocking At The Door: Challenges Women Face With Biopharma Boards September 28, 2020 Biopharma’s COVID Capital Comeback – A Whitepaper September 14, 2020 Live Panel: The Unexpected IPO Boom for Biopharma in Q2 July 22, 2020 Q2 2020 Report: Global Trends in Biopharma Transactions July 9, 2020 Live Panel: Brave New World: Challenges from the East, Asia Biopharma, and Response to COVID-19 June 25, 2020 A Brave New World: Japan Pharma and COVID-19 June 23, 2020 Deal Makers of Japan, Volume 2 June 15, 2020 Panel Recording on 6.11: Accessing Capital in the Time of COVID June 8, 2020 Panel Recording on 5.7: Biopharma Deal Maker’s Guide to Strategic Partnerships May 12, 2020 Panel Recording on 4.16: Q1 2020 Biopharma Market Conditions Live Panel April 17, 2020 Q1 2020 Report: Global Trends in Biopharma Transactions April 13, 2020 LIVE Panel Discussion: Q1 2020 Biopharma Market Conditions April 11, 2020 Panel Recording on 4.2: Strategic Implications of COVID-19 on Biopharma Companies & Investors April 6, 2020 LIVE Panel Discussion, COVID-19: Strategic Implications on Biopharma March 31, 2020 Strategic Implications of COVID-19 on Biopharma March 20, 2020 Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships March 19, 2020 Deal Makers of Japan, Volume 1 March 3, 2020 2019 Year End Review Biopharma Report January 11, 2020 2019 Medtech Year End Review Report January 11, 2020 Q3 2019 Report: Global Trends in Medtech Transactions October 11, 2019 Q3 2019 Global Trends in Biopharma Transactions October 11, 2019 Whitepaper Download: Inside Out September 16, 2019 My (National Lampoon’s) European Vacation August 21, 2019 Financing overhang or hangover: The impact on partnerships for public biotech companies July 30, 2019 Q2 2019 Report: Global Trends in Biopharma Transactions July 17, 2019 Q2 2019: Global Trends in Medtech Transactions July 17, 2019 Brian Coleman of Locust Walk to Moderate Panel at BioEquity Europe: Drawing Your Financing Roadmap May 20, 2019 Global Business Reports Interview with Geoff Meyerson, CEO & Co-Founder of Locust Walk May 6, 2019 Greed is Bad: Why Defendable Commercial Assessments are Better Than Pie in the Sky April 30, 2019 Q1 2019: Global Trends in Medtech Transactions April 11, 2019 Q1 2019 Report: Global Trends in Biopharma Transactions April 11, 2019 The Art of the Multi-Track Deal Whitepaper April 8, 2019 Make No Bones About It – AAOS 2019 Was All About M&A and Promising New Technology March 20, 2019 The Asia Factor Whitepaper March 11, 2019 Trends in Venture Deal Term Sheets: Favorable Climate for Founders February 22, 2019 2018 Annual Trends in Medtech Transactions Report February 4, 2019 2018 Annual Trends in Biopharma Transactions Report February 4, 2019 Q3 2018 Trends in Biopharma Transactions Report October 18, 2018 Q3 2018 Trends in Medtech Transaction Report October 18, 2018 Q2 2018 Trends in Medtech Transactions Report July 13, 2018 Q2 2018 Trends in Biopharma Transactions July 13, 2018 Locust Walk supports 2018 Diabetes Innovation Challenge May 7, 2018 Q1 2018 Trends in Biopharma Transactions Report April 11, 2018 Q1 2018 Trends in Medtech Transactions Report April 11, 2018 Indication Selection for a Platform Company: The Faustian Dilemma December 13, 2017 Explain Yourself! Avoiding Common Communications Pitfalls During Term Sheet Negotiations December 6, 2017 Japan & China: So close yet so different November 30, 2017 Late-Stage Biopharma IPOs and the Commercialization Partnership – Predictor of Success? November 21, 2017 Maximizing Your JP Morgan Healthcare Conference November 15, 2017 Finding the invisible, how to meet Family Offices November 2, 2017 Navigating the MedTech Fundraising Environment October 25, 2017 Demystifying the Venture Capital Term Sheet October 11, 2017 Q3 2017 Trends in Life Sciences Finance October 11, 2017 When to use a structured deal process? October 5, 2017 Key trends impacting Japan partnering September 13, 2017 Getting Taken to School: Key Considerations and Differentiators of why “Academic” Transactions Have Typically Lower Deal Values than Industry Transactions August 29, 2017 Maximizing the Likelihood of Closing a Deal This Year August 15, 2017 Why is Family Office money so hard to find for life science companies? August 8, 2017 Ask the Experts: The Importance of Including Subject Matter Experts in Deal Discussions August 2, 2017 Q2 2017 Trends in Life Science Finance July 6, 2017 Helping to Ensure Success After the Deal June 21, 2017 The Best Buyers Are The Best Sellers June 6, 2017 Maintaining Deal Momentum in the Summertime May 31, 2017 Looking at Deal Value Beyond the Headlines May 24, 2017 Companies are bought, because they are sold May 17, 2017 Finding the Right Partner May 3, 2017 Looking East – Geographic Considerations when Partnering Regionally in Asia April 26, 2017 Looking East – Geographic Considerations when Partnering Regionally in Asia April 26, 2017 It’s Not You, It’s US: The Value of Keeping US Rights in Biopharma Partnering April 25, 2017 Q1 2017 Trends in Biotech Finance April 17, 2017 Executing a successful buy-side transaction for commercial stage companies April 12, 2017 Deal Strategy and Objectives March 29, 2017
